Compare POST & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POST | APGE |
|---|---|---|
| Founded | 1895 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 4.7B |
| IPO Year | 2011 | 2023 |
| Metric | POST | APGE |
|---|---|---|
| Price | $105.59 | $74.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 11 |
| Target Price | ★ $127.33 | $102.40 |
| AVG Volume (30 Days) | 708.5K | ★ 780.2K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | ★ $8,158,100,000.00 | N/A |
| Revenue This Year | $4.94 | N/A |
| Revenue Next Year | $0.42 | N/A |
| P/E Ratio | $61.75 | ★ N/A |
| Revenue Growth | ★ 2.97 | N/A |
| 52 Week Low | $95.07 | $26.20 |
| 52 Week High | $119.85 | $84.56 |
| Indicator | POST | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 49.38 | 59.76 |
| Support Level | $101.92 | $73.06 |
| Resistance Level | $109.31 | $82.77 |
| Average True Range (ATR) | 2.15 | 3.60 |
| MACD | -0.48 | 0.76 |
| Stochastic Oscillator | 39.53 | 94.40 |
Post Holdings Inc. is a consumer packaged goods holding company with products sold through grocery, club, and drug stores, mass merchandisers, foodservice, food ingredient, and eCommerce. It operates through four reportable segments: Post Consumer Brands, focused on North American ready-to-eat cereal and granola, pet food, and nut butters; Weetabix, focused on U.K. ready-to-eat cereal, muesli, and protein-based shakes; Foodservice, focused on egg and potato products; and Refrigerated Retail, focused on side dish, egg, cheese, and sausage products. Products are sold across channels, including retailers, wholesalers, convenience stores, pet supply retailers, drug store customers, military and national restaurant chains, with revenues largely generated in the U.S.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.